Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.
about
Lymphoma Immunotherapy: Current StatusTargeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in miceIdiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaTargeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cellsTowards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphomaStructural basis for the recognition in an idiotype-anti-idiotype antibody complex related to celiac disease.Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.Immunotherapy for B-cell lymphoma: current status and prospective advancesBrief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.New developments in immunotherapy for lymphoma
P2860
Q26782902-2D0F5AA5-B3FB-46F2-B203-392EB157E32BQ33989839-67A6EA82-C29F-4179-9950-A9C0090857F5Q35113388-D4F923E9-EBA6-4270-AB4B-5694FF8EFF21Q35114545-E1C94983-9F63-463B-9996-3F63447F012AQ35141490-ABD9E197-534E-481E-A872-70F36EC50E58Q35144751-94D536F3-5021-4A24-8121-52D127BF3FA9Q35154940-2A7CF5B3-A196-4C0C-B6B7-FE8EBEA79796Q35215675-8B506B59-877F-4C0D-B715-2BFA681A6105Q36074726-EB60E79C-9A58-41AE-8528-6C00106B8ECAQ36194235-022C6250-1C73-478E-8F75-E3E4BB4BA50AQ37505384-4AF2D083-16CB-4042-A06E-84C743DD383FQ38839148-0B988762-7AAC-47D9-A319-86AD293BC967Q41831989-56FB28D5-E56B-4BB5-AD51-C39A07963A28Q47559036-966F5AD9-2796-4ABA-A15C-31213A73D7A8Q58804962-9DE0E16F-86A0-4AB7-BC76-3365F30E27C1
P2860
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Developing idiotype vaccines f ...... to phase III clinical trials.
@en
Developing idiotype vaccines f ...... to phase III clinical trials.
@nl
type
label
Developing idiotype vaccines f ...... to phase III clinical trials.
@en
Developing idiotype vaccines f ...... to phase III clinical trials.
@nl
prefLabel
Developing idiotype vaccines f ...... to phase III clinical trials.
@en
Developing idiotype vaccines f ...... to phase III clinical trials.
@nl
P2860
P1476
Developing idiotype vaccines f ...... to phase III clinical trials.
@en
P2093
Hyun Jun Park
Sattva S Neelapu
P2860
P304
P356
10.1111/J.1365-2141.2008.07143.X
P407
P577
2008-04-13T00:00:00Z